Supernus Pharmaceuticals announced a merger with Indivior Pharmaceuticals in an all-stock deal, creating a combined company with 11 FDA-approved drugs and anticipated $125 million in annual cost synergies. The stock rose 3% despite initial gains of 16%, reflecting cautious optimism. Q2 earnings showed 32% revenue growth to $219 million but a net loss of $58 million, missing earnings estimates while beating revenue forecasts.

Indivior Pharmaceuticals announced it will report its second quarter 2026 financial results on August 4, 2026, followed by a live webcast presentation at 8:00 a.m. EDT with CEO Joe Ciaffoni and leadership team members. The company will discuss its performance as a leader in long-acting injectable treatments for opioid use disorder.

Herantis Pharma announced positive FDA feedback on its Phase 2a study design for HER-096, a lead candidate for Parkinson's disease treatment. The company has finalized the study design to enroll approximately 100 patients and secured over 50% of Phase 2 funding. The FDA raised no concerns regarding chemistry, manufacturing, controls, or preclinical data, and confirmed readiness for U.S. clinical site activation.

Divisadero Street Capital Management sold 2.26 million shares of Indivior (INDV) for approximately $74.76 million in Q1 2026, reducing its stake to 521,083 shares. The sale appears to be profit-taking after the stock surged nearly 200% over the past year. Despite the fund's exit, Indivior's fundamentals remain strong with Q1 revenue up 19% year-over-year to $317 million and SUBLOCADE sales jumping 32% to $232 million, prompting management to raise 2026 guidance.

Indivior presented new real-world data at the ASAM 2026 Annual Conference demonstrating that SUBLOCADE (monthly injectable buprenorphine) accounts for the smallest proportion of non-fatal and fatal overdose events compared to other medications for opioid use disorder. The company also presented findings from the ROUTE Study showing that remission from OUD correlates with improved quality of life, lower craving, and better functional outcomes beyond abstinence alone.

Indivior Pharmaceuticals (INDV) announced it will report first quarter 2026 financial results on April 30, 2026, followed by a live webcast presentation at 8:00 a.m. EDT with CEO Joe Ciaffoni and leadership team. The company highlighted a cost impact model showing its monthly injectable buprenorphine treatment (SUBLOCADE) may reduce staffing burdens and costs in correctional facilities compared to other opioid use disorder medications.

Indivior Pharmaceuticals priced a $450 million offering of 0.625% convertible senior notes due 2031, upsized from the initially announced $400 million. The notes have a conversion price of approximately $41.66 per share (35% premium to market price) and will mature on March 15, 2031. Net proceeds of approximately $437.7 million will be used to repay existing debt ($239 million plus $102 million cash on hand), repurchase approximately 2.4 million shares ($75 million), and fund general corporate purposes.

Indivior Pharmaceuticals announced its intention to offer $400 million in convertible senior notes due 2031 in a private placement to qualified institutional buyers. The company plans to use approximately $239 million of net proceeds to repay existing term loan and revolving credit facility borrowings, up to $75 million for share repurchases, and the remainder for general corporate purposes. The notes will be convertible into common stock under specified conditions and redeemable after March 2029.

Indivior Pharmaceuticals announced it will report its Q4 and full-year 2025 financial results on February 26, 2026, followed by a leadership webcast. The company also completed its redomiciliation from the United Kingdom to the United States and provided 2026 financial guidance projecting total net revenue between $1,125-$1,195 million, with SUBLOCADE net revenue expected at $905-$945 million.

Indivior reported strong Q3 results, upgrading full-year guidance for Sublocade sales to $825-$845 million. The company is executing a three-phase growth strategy focused on increasing U.S. sales and achieving expense savings.

A comprehensive market research report analyzing the Cannabis Use Disorder pipeline, featuring over 5 companies developing novel treatments for addressing CUD challenges.

Addex Therapeutics announced that it will present preclinical data on its GABAB positive allosteric modulator cough program at the American Cough Conference. The company's lead drug candidate is ready to start IND enabling studies.